Glaukos - Increasing treatment numbers significantly boost results!
Reading Time: 1 minute
Business driver: Glaukos (GKOS) specializes in minimally invasive techniques and micro-implants for the treatment of glaucoma, which is considered one of the most common causes of blindness. Among micro-implants, Glaukos is one of the leading providers in this segment with iStent inject W, which helps reduce intraocular pressure in patients with diagnosed primary open-angle glaucoma. With the FDA approval of the eye implant IDose TR, Glaukos achieved a significant breakthrough at the end of 2023. Fresh momentum is anticipated from Glaukos' newly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
